We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay.
- Authors
Fogolari, Marta; Leoni, Bruno Daniele; De Cesaris, Marina; Italiano, Rita; Davini, Flavio; Miccoli, Ginevra Azzurra; Donati, Daniele; Clerico, Luigi; Stanziale, Andrea; Savini, Giovanni; Petrosillo, Nicola; Ciccozzi, Massimo; Sommella, Lorenzo; Riva, Elisabetta; Fazii, Paolo; Angeletti, Silvia
- Abstract
Background: Monitoring antibody response following SARS-CoV-2 vaccination is strategic, and neutralizing antibodies represent the gold standard. The neutralizing response to Beta and Omicron VOCs was evaluated versus the gold standard by a new commercial automated assay. Methods: Serum samples from 100 healthcare workers from the Fondazione Policlinico Universitario Campus Biomedico and the Pescara Hospital were collected. IgG levels were determined by chemiluminescent immunoassay (Abbott Laboratories, Wiesbaden, Germany) and serum neutralization assay as the gold standard. Moreover, a new commercial immunoassay, the PETIA test Nab (SGM, Rome, Italy), was used for neutralization evaluation. Statistical analysis was performed with R software, version 3.6.0. Results: Anti-SARS-CoV-2 IgG titers decayed during the first ninety days after the vaccine second dose. The following booster dose significantly (p < 0.001) increased IgG levels. A correlation between IgG expression and neutralizing activity modulation was found with a significant increase after the second and the third booster dose (p < 0.05. Compared to the Beta variant of the virus, the Omicron VOC was associated with a significantly larger quantity of IgG antibodies needed to achieve the same degree of neutralization. The best Nab test cutoff for high neutralization titer (≥1:80) was set for both Beta and Omicron variants. Conclusion: This study correlates vaccine-induced IgG expression and neutralizing activity using a new PETIA assay, suggesting its usefulness for SARS-CoV2 infection management.
- Subjects
SARS-CoV-2 Omicron variant; BOOSTER vaccines; MEDICAL personnel; COVID-19 vaccines; IMMUNOGLOBULINS
- Publication
Diagnostics (2075-4418), 2023, Vol 13, Issue 5, p889
- ISSN
2075-4418
- Publication type
Article
- DOI
10.3390/diagnostics13050889